Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score
The DELTA‑P score predicts the likelihood of underlying small‑cell lung cancer in patients newly diagnosed with Lambert‑Eaton myasthenic syndrome.
Indications for Use
Identifies in newly diagnosed LEMS patients their probability of underlying SCLC and guides intensity of early tumor screening. Applies at or within 3 months of symptom onset using six clinical predictors; high scores (4–6) indicate >93% SCLC risk, while 0–1 predicts ≤2.6% risk (derivation n=107; validation n=112; AUC ~94% 1 [Level I evidence]). Clinically useful for stratifying surveillance with CT‑thorax and FDG‑PET.
Insights & Cautions
Identifies high or low SCLC probability in newly diagnosed LEMS using six bedside variables. High discrimination (AUC ≈94% in derivation/validation cohorts) 1 [Level II evidence].
Cautions: Derived from two European cohorts only; performance drops in some real‑world settings; not a substitute for repeated thoracic imaging; SOX1 antibodies may add specificity; risk estimates become unreliable beyond early disease.